Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Tatnic who wrote (6304)	4/8/1999 10:19:00 AM
From: Linda Kaplan	Respond to of 7041

I guess they figured since they had NO sales in Mexico after approval, (and that was the ONLY country it which Vasomax was approved) they'd make up for it in the US, if approved. duh! At the time of Mexico approval it was supposed to be a prototype for great sales, and now it's supposed to be an anomaly because it generated NO sales. Stock price went down a bunch during the time it took me to edit my notes here. Linda

To: Tatnic who wrote (6304)	4/8/1999 11:27:00 PM
From: VLAD	Read Replies (1) \| Respond to of 7041

Perhaps the Schering analyst was tracking what was said regarding Vasomax at the EAU meeting in Stockholm on April 7th: uroweb.org Note the satellite symposia entitled "Recent advances and treatment of male erectile dysfunction"(Sponsored by an educational grant by Schering-Plough). Apparently nobody was impressed with the marginal results of oral phentolamine but since it is a pill that may make an old man's dick hard it will always have a certain degree of appeal regardless of how well it works.